179 related articles for article (PubMed ID: 27142582)
1. Safety of available treatment options for renal cell carcinoma.
Derosa L; Albiges L; Massard C; Loriot Y; Fizazi K; Escudier B
Expert Opin Drug Saf; 2016 Aug; 15(8):1097-106. PubMed ID: 27142582
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy.
Diamond E; Molina AM; Carbonaro M; Akhtar NH; Giannakakou P; Tagawa ST; Nanus DM
Crit Rev Oncol Hematol; 2015 Dec; 96(3):518-26. PubMed ID: 26321263
[TBL] [Abstract][Full Text] [Related]
3. Renal cell carcinoma: molecular biology and targeted therapy.
Su D; Stamatakis L; Singer EA; Srinivasan R
Curr Opin Oncol; 2014 May; 26(3):321-7. PubMed ID: 24675233
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapies for metastatic renal cell carcinoma in older adults.
Pal SK; Vanderwalde A; Hurria A; Figlin RA
Drugs Aging; 2011 Aug; 28(8):635-49. PubMed ID: 21812499
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.
Liu KG; Gupta S; Goel S
Oncotarget; 2017 Mar; 8(10):17313-17327. PubMed ID: 28061473
[TBL] [Abstract][Full Text] [Related]
6. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.
Gore ME; Larkin JM
Br J Cancer; 2011 Feb; 104(3):399-406. PubMed ID: 21285971
[TBL] [Abstract][Full Text] [Related]
7. Toxicity Management of Systemic Kidney Cancer Therapies.
Qin Q; Nein E; Flaten A; Zhang T
Hematol Oncol Clin North Am; 2023 Oct; 37(5):993-1003. PubMed ID: 37353375
[TBL] [Abstract][Full Text] [Related]
8. Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies.
Larkin JM; Pyle LM; Gore ME
Oncologist; 2010; 15(11):1135-46. PubMed ID: 21051659
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience.
Mennitto A; Grassi P; Ratta R; Verzoni E; Prisciandaro M; Procopio G
Ther Adv Urol; 2016 Oct; 8(5):319-326. PubMed ID: 27695530
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma.
Sonpavde G; Choueiri TK
Br J Cancer; 2012 Sep; 107(7):1009-16. PubMed ID: 22948724
[TBL] [Abstract][Full Text] [Related]
11. Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function.
Mielczarek Ł; Brodziak A; Sobczuk P; Kawecki M; Cudnoch-Jędrzejewska A; Czarnecka AM
Cancer Chemother Pharmacol; 2021 Jun; 87(6):723-742. PubMed ID: 33768301
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant immunotherapy for locally advanced renal cell carcinoma.
Alevizakos M; McDermott D
Expert Opin Biol Ther; 2023; 23(12):1265-1275. PubMed ID: 38069655
[TBL] [Abstract][Full Text] [Related]
13. First Line Medical Treatment of Metastatic Renal Cell Carcinoma: A Podcast on Choosing Wisely and Managing Safely.
Ivanyi P; Wiegmann JP; Eggers H; Grünwald V
Adv Ther; 2023 Sep; 40(9):3620-3625. PubMed ID: 37438555
[TBL] [Abstract][Full Text] [Related]
14. The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma.
Su J; Zhou L; Zhang Z; Xiao X; Qin Y; Zhou X; Huang T
Front Immunol; 2023; 14():1146738. PubMed ID: 37350955
[TBL] [Abstract][Full Text] [Related]
15. Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Studentova H; Hola K; Melichar B; Spisarova M
Expert Rev Anticancer Ther; 2024 Jun; 24(6):339-345. PubMed ID: 38596831
[TBL] [Abstract][Full Text] [Related]
16. Role of immunotherapy for renal cell cancer in 2011.
George S; Pili R; Carducci MA; Kim JJ
J Natl Compr Canc Netw; 2011 Sep; 9(9):1011-8. PubMed ID: 21917625
[TBL] [Abstract][Full Text] [Related]
17. A new age for vaccine therapy in renal cell carcinoma.
Pal SK; Hu A; Figlin RA
Cancer J; 2013; 19(4):365-70. PubMed ID: 23867519
[TBL] [Abstract][Full Text] [Related]
18. The challenges of adoptive cell transfer in the treatment of human renal cell carcinoma.
Strizova Z; Bartunkova J; Smrz D
Cancer Immunol Immunother; 2019 Nov; 68(11):1831-1838. PubMed ID: 31222485
[TBL] [Abstract][Full Text] [Related]
19. Combination drug regimens for metastatic clear cell renal cell carcinoma.
Khetani VV; Portal DE; Shah MR; Mayer T; Singer EA
World J Clin Oncol; 2020 Aug; 11(8):541-562. PubMed ID: 32879843
[TBL] [Abstract][Full Text] [Related]
20. How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists.
Tucci M; Cosmai L; Pirovano M; Campisi I; Re SGV; Porta C; Gallieni M; Piergiorgio M
Cancer Treat Rev; 2024 Apr; 125():102692. PubMed ID: 38492515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
